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Abstract
Background: Because retroperitoneal soft tissue sarcomas (RPS) are extremely rare, there is a significant lack of
clinicopathologic information to optimize the treatment strategy. The aim of this study was to evaluate the prognostic
factors in RPS, with particular focus on the Ki-67 labeling index (LI).
Methods: We included the data from a total of 23 patients who received treatment for primary RPS at a single center.
The variables analyzed in this study included tumor size, histological type, malignancy grade, necrosis, mitosis, and
Ki-67 LI. Kaplan-Meier and Cox proportional regression analyses of overall survival (OS) were performed to identify
significant prognostic variables.
Results: Of the 23 patients who underwent surgical resection, 9 (39 %) underwent simple resection of the tumor and
14 (61 %) extended resection including the adjacent organs. In the univariate analysis, a simple tumor resection and a
high Ki-67 LI were associated with shorter OS. The multivariate analysis revealed that simple tumor resection and a
high Ki-67 LI were independent negative prognostic factors for OS.
Conclusions: Our results suggested that combined resection of RPS and its adjacent organs improved OS. Pathologically,
a high Ki-67 LI was significantly associated with negative prognosis.
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Background
Retroperitoneal soft tissue sarcomas (RPS) are uncom-
mon tumors, accounting for approximately 12 % of soft
tissue sarcomas [1]. The mean annual incidence is ap-
proximately 2.7 per 100,000 [2], and the 5-year survival
is approximately 50 % [3]. Local recurrence is common
(41–68 %), and metastases occur in one third of the pa-
tients after surgical resection [3]. Local recurrence is the
leading cause of death in patients with RPS. Surgery is
currently the only modality that offers a chance of cure.
Extended resection including the adjacent organs is sug-
gested regardless of the presence of neoplastic infiltration
[4–7]. On the other hand, the surgery for RPS presents
specific challenges due to the location in a complex space
surrounded by vital structures and visceral organs, and an
extended surgery is not practical in all cases [8–10]. Adju-
vant therapy such as radiotherapy and/or systemic chemo-
therapy is usually considered because the risk of local
recurrence after surgery alone is relatively high.
Prognostic factors in RPS are important for selecting
appropriate therapies and follow-up after surgical resec-
tion. The currently used prognostic factors include age,
tumor size, histopathological type, malignancy grade,
and positive resection margins; these are combined into
different prognostic systems [3, 5, 11–15]. To improve
the prognostic accuracy, researchers have been trying to
incorporate an assessment of the biological features,
such as proliferation activity, into the prediction tools
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for disease prognosis. The Ki-67 labeling index (LI),
assessed with immunohistochemical staining using a
mouse monoclonal antibody named MIB-1 clone, and
based on the proportion of Ki-67-positive tumor cells, is
known to be useful for objective histopathological evalu-
ation of the tumor proliferation activity. A high Ki-67 LI
is associated with poor prognosis in soft tissue sarcomas
[16, 17]. Ki-67 has also been recognized as essential for
diagnosing tumor grade. The purpose of this study was
to evaluate the currently used prognostic factor and to
clarify the prognostic significance of Ki-67 in RPS in a
Japanese single-center cohort.
Methods
Patients and data collection
The Nara Medical University institutional review board
approved this study, and all participants provided in-
formed consent. This is a retrospective study of 26
cases with RPS, treated between January 2002 and Janu-
ary 2014 at Nara Medical University. In three patients,
only needle biopsy was carried out for the verification
of pathology, because significant comorbidities and/or
advanced stage made them unsuitable for a radical re-
section. One of these patients was treated with pallia-
tive care alone, one with radiation therapy, and one
with chemotherapy. These three patients were ex-
cluded, leaving 23 cases. The type of surgery was cate-
gorized into two groups: simple resection (surgical
resection of the tumor mass only) and extended resec-
tion (surgical resection of the tumor mass and the adja-
cent organs). All the hematoxylin and eosin (H&E)-
stained specimens were re-evaluated for diagnosis by
two experienced pathologists (KS and KN), following
the World Health Organization (WHO) criteria for
classification of soft tissue tumors [18]. The tumor vari-
ables analyzed included tumor size, histological type,
malignancy grade [19], presence of necrosis, and cell
mitosis.
Calculation of the Ki-67 labeling index
Immunohistochemical (IHC) staining for Ki-67 was per-
formed with a streptavidin-biotin (SAB) complex
method using the Histofine SAB-PO kit (Nichirei Co.,
Tokyo, Japan) according to the manufacturer’s direc-
tions. For antigen retrieval, the sections were routinely
autoclaved for 10 min in 0.01 M citrate buffer (pH 6.0).
The primary antibody was monoclonal mouse anti-Ki-67
antigen (clone MIB-1, Dako, Japan), ready to use at
room temperature for 30 min. The sections were coun-
terstained with Meyer’s hematoxylin and mounted with
Malinol and were examined alongside H&E-stained speci-
mens, to identify the precise locations of the lesions. Five
independent areas in the sections were selected with a
high-power field (×400) and saved as pictures. IHC
evaluation was carried out by two investigators (YM and
YT). Evaluation was performed blindly without know-
ledge of the patients’ outcome and other clinicopatho-
logic characteristics. The percentages of positive cells
(Ki-67 LI) were calculated. The cutoff point was deter-
mined by a receiver operating characteristics (ROC)
curve for tumor recurrence.
Statistical analysis
The primary endpoint was overall survival (OS). The
cutoff date of the last follow-up was December 31, 2015.
The OS was computed from the date of primary tumor
resection to the date of death or the last follow-up and
examined using the Kaplan-Meier method. Univariate
and multivariate analyses were performed for OS using
the Cox proportional hazards models. All tests were
two-sided. The results of Cox model analysis are re-
ported with relative risks and 95 % confidence intervals
(CIs). IBM SPSS version 21 (SPSS Inc., Chicago, IL) and
PRISM software version 5.00 (GraphPad Software, Inc.,
San Diego, CA) were used for statistical analyses and
data plotting, respectively. A P value of <0.05 was con-
sidered statistically significant.
Results
Patient characteristics and clinical and operative findings
The median patient age was 62.5 years (range 31–
79 years). There were 15 male (65 %) and 8 female par-
ticipants (35 %). The clinicopathologic variables of the
patients and primary tumors are presented in Table 1.
Nine received a simple resection of the tumor and 14 an
extended resection including the adjacent organs. Type
of surgery was decided by preoperative imaging or in-
traoperative examination. Ten patients underwent the
extended resection because they were diagnosed as in-
filtration into the adjacent organs by preoperative im-
aging. In one of these ten patients, whose tumor
infiltrated to the kidney and diaphragm, only the tumor
and kidney were resected. Four patients underwent the
extended resection because the surgeons suspected the
infiltration by intraoperative examination. One patient
who was diagnosed as infiltration into the adjacent or-
gans performed the simple resection because resection
of the adjacent organs was impossible for tumor adhe-
sion. The main resected organs were the kidney (6/10,
60 %), colon (4/10, 40 %), and bladder (3/10, 30 %). In
four patients, two adjacent organs were resected, and in
two patients, three organs were resected en bloc. In all
patients, there were no major perioperative complica-
tions more than grade 2 in Clavien classification.
Pathological findings
The majority of the tumors were of high grade, and the
most common histology was liposarcoma (52 %). Other
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histologies included leiomyosarcoma (17 %), malignant
fibrous histiocytoma (MFH) (14 %), and others (synovial
sarcoma, epithelioid sarcoma, Ewing’s sarcoma, and not
otherwise-specified sarcoma). Histological type other
than liposarcoma (non-liposarcoma), tumor necrosis, cell
mitosis, and malignancy grade were used as prognostic
factors for RPS. Cox analysis was performed to evaluate
the association between these factors and OS. None of
them was significant.
The Ki-67 LI was evaluated in all cases (Fig. 1). The
median Ki-67 LI was 25 % (range 2–53 %). The cutoff
point was determined as 25 % according to the ROC
Table 1 Clinicopathologic background according to the disease status
Variables All (n = 23) Simple resection (n = 9) Extended resection (n = 14) P value
Median age, years (IQR) 62 (51.5–71) 62 (42–70) 62 (52.5–71) 0.68a
Sex, n (%) 0.57b
Men 15 (65 %) 7 (78 %) 8 (57 %)
Women 8 (35 %) 2 (22 %) 6 (43 %)
Follow-up, months (IQR) 30 (18–51.5) 19 (18–33) 30.5 (24–87.5) 0.12a
Tumor size, mm (IQR) 77 (50–210) 80 (50–120) 75 (51–112) 0.99a
Symptoms positive, n (%) 0.87b
Yes 12 (52 %) 4 (44 %) 8 (57 %)
No 11 (48 %) 5 (56 %) 6 (43 %)
Infiltration into the adjacent organs, n (%) 0.01*,b
Yes 11 (48 %) 1 (11 %) 10 (71 %)
No 12 (52 %) 8 (89 %) 4 (29 %)
Margins, n (%) 0.94b
R0 4 (17 %) 2 (22 %) 2 (14 %)
R1 17 (74 %) 6 (67 %) 11 (79 %)
R2 2 (9 %) 1 (11 %) 1 (7 %)
Histological type, n (%) 0.87b
Liposarcoma 12 (52 %) 4 (44 %) 8 (57 %)
Leiomyosarcoma 4 (17 %) 2 (22 %) 2 (14 %)
MFH 3 (14 %) 1 (11 %) 2 (14 %)
Other 4 (17 %) 2 (22 %) 2 (14 %)
Tumor grade, n (%) 0.82b
Grade 1 3 (14 %) 1 (11 %) 2 (14 %)
Grade 2 4 (17 %) 2 (22 %) 2 (14 %)
Grade 3 16 (69 %) 6 (67 %) 10 (71 %)
Necrosis, n (%) 0.88b
Yes 17 (74 %) 7 (78 %) 10 (71 %)
No 6 (26 %) 2 (22 %) 4 (29 %)
Mitosis, n (%) 0.61b
1–9/10HPF 14 (61 %) 5 (56 %) 9 (64 %)
10–20/HPF 9 (39 %) 4 (44 %) 5 (36 %)
Ki-67 LI, n (%) 0.42b
<25 % 13 (56 %) 4 (44 %) 9 (64 %)
≥25 % 10 (44 %) 5 (56 %) 5 (36 %)
Simple resection: resection of only the tumor; extended resection: resection extended to adjacent organs; tumor grade: using the French Federation of Cancer
Centers Sarcoma Group grading system
IQR interquartile range, R0 microscopically negative margin, R1 microscopically positive margin, R2 gross residual margin, MFH malignant fibrous histiocytoma,
HPF high-power field, Ki-67 LI Ki-67 labeling index
aMann-Whitney test
bFisher’s exact test or chi-square with Yates’ correction
* = P <0.05
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curve for tumor recurrence. To evaluate the prognostic
significance of the Ki-67 LI, the Kaplan-Meier and the
COX analyses were performed. In univariate analysis, tu-
mors with a Ki-67 LI of 25 % or more showed worse
prognosis than those with a Ki-67 LI of less than 25 %
(P = 0.001). Non-liposarcoma histopathology was not a
negative prognostic factor compared to liposarcoma
histopathology in our cohort; however, there was a sig-
nificant association between a high Ki-67 LI and histo-
logical type (P = 0.047, median Ki-67 LI = 28.48 and
18.90 in liposarcoma and non-liposarcoma, respectively).
Follow-up and overall survival
The median follow-up period was 30 months (range 6–
116 months) after surgical resection. Of the 13 patients
experiencing recurrence, 6 patients experienced local re-
currence in the original tumor site, whereas 7 patients de-
veloped distant metastasis. The most common site of
distant metastasis was lung (in four patients). Eleven pa-
tients died of tumor progression in 6 months after recur-
rence. Ten patients did not present evidence of disease
recurrence after surgical resection, and the median OS
was 52 months. In univariate Kaplan-Meier analyses, the
extended resection including the adjacent organs was as-
sociated with the probability of OS (3-year OS 78 % vs.
0 %, Fig. 2b). Ki-67 LI was associated with the probability
of OS (3-year OS 69 % vs. 27 %, Fig. 2c). In multivariate
Cox models, age, symptoms, tumor size, resection mar-
gins, histological type, tumor grade, and necrosis were not
significant prognostic factors for OS, while the type of sur-
gery and the Ki-67 LI were significant (Table 2). In multi-
variate analysis, simple resection and high Ki-67 LI were
independent predictive factors for decreased OS (Table 2).
Discussion
RPS is a rare neoplasm and is usually locally advanced at
the time of diagnosis [3]. The mainstay of treatment is
surgery. The RPS borders with the surrounding organs,
including the kidney, adrenal, colon, ureter, bladder,
spleen, pancreas, and psoas, are usually difficult to iden-
tify. Essentially all the macroscopic total resections con-
sist of marginal excisions through the reactive zone
surrounding the tumor; therefore, the margins are
microscopically positive in the majority of the patients,
and the probability of local recurrence after surgery
alone is high [1, 2, 7]. In this study, the resection margin
had no relevance to OS. The rate of positive resection
margin (R1 or R2) was very high (83 %,19/23); neverthe-
less, the extended resection of adjacent organs, regard-
less of resection margin positivity, was a significant
predictor of OS.
In contrast to the more common epithelial tumors,
which develop within a single organ, RPS can infiltrate
multiple surrounding organs [20]. The oncologic benefit
Fig. 1 Ki-67 immunohistochemical staining of two representative cases of retroperitoneal liposarcoma. Case 1 was diagnosed with liposarcoma
with a Ki-67 labeling index of 50 %. He experienced local recurrence and lung metastasis 19 months after surgical resection and died 18 months
after surgical resection. Case 2 was diagnosed with liposarcoma with a Ki-67 labeling index of 2 %. He was alive without any evidence of disease
recurrence at the last visit, 108 months after the surgical resection
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of extended surgery is associated with a lower rate of
local recurrence [6, 7]. However, the feasibility of such
resection is variable, depending on the exact relation-
ships of the tumor with other structures within the
anatomical complexity of the retroperitoneum. Resec-
tion of more than three adjacent organs has been
shown to be associated with a significantly higher
complication rate than the resection of fewer organs
[10]. In this study, resections of three adjacent organs
were performed in two patients and of one or two or-
gans in 12 patients; in all these cases, there were no
major perioperative complications. In one case of
tumor infiltration into multiple adjacent organs, a
complete resection was not attempted. Although the
extended resection of adjacent organs regardless of
tumor infiltration is the gold standard [6, 7, 21], sig-
nificant controversy persists regarding the benefit and
associated morbidity of multi-organ resection. Some
authors have proposed to perform surgery with the
goal of complete macroscopic resection and to resect
contiguous organs only when directly infiltrated [8–
10]. Four patients who subjected to extended resection
did not show tumor infiltration to the adjacent organs
by diagnostic imaging, but the surgeons suspected the
direct infiltration to contiguous organs by intraopera-
tive examination. All of them did not experience
recurrence.
Tumor size, malignancy grade, positive margins, and
histological type are currently used as prognostic factors
for RPS [3, 5, 11–15, 19]. In this study, high expression
of Ki-67 was a significant predictor of OS. The Ki-67
antigen is a cell cycle-associated nuclear protein and is
present in all stages of the cell cycle (G1, S, G2, and M
phases) in proliferating cells but is absent in G0 and
early G1 phases of cells re-entering the cell cycle [22].
The antibody against Ki-67 has been documented to be
useful for the diagnosis and prognosis of some neo-
plasms. The Ki-67 LI is correlated with shorter disease-
specific survival in soft tissue sarcomas [16, 17] and is
expected to be one of the adverse prognostic factors in
RPS. Because the risk of local recurrence after surgery
alone is very high, adjuvant therapy should be consid-
ered [3]. Adjuvant chemotherapy or radiotherapy im-
proved local tumor control in high-risk patients [23–25].
Therefore, the high-Ki-67 LI group represents a good
candidate for adjuvant therapy.
This investigation confirmed the finding that, in
patients with primary RPS, extended resection of the
adjacent organs was an independent prognostic
factor. However, in patients whose tumors do not in-
filtrate the adjacent organs according to clinical im-
aging, it is problematic to decide if the adjacent
organs should be resected en bloc. In nine patients
who subjected to simple tumor resection, eight did
not show tumor infiltration to the adjacent organs by
diagnostic imaging or intraoperative examination. But
because seven of these eight patients experienced evi-
dence of disease recurrence, extended resection
including the adjacent organs might have been re-
quired to remove the whole tumor burden.
Fig. 2 Kaplan-Meier curves of overall survival (OS) after surgical
resection. a OS in all cases. All the events were due to tumor
progression. b OS according to the type of surgery. The extended
surgery improved OS in RPS. c OS according to the Ki-67 labeling
index. P values were calculated using the log-rank test
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Preoperative core needle biopsy in RPS has been re-
ported to be useful to obtain a histological diagnosis
[26]. The assessment of the Ki-67 LI by preoperative
biopsy would allow selection of the appropriate oper-
ation method.
The limitations of the present study include a small
sample size and the retrospective analysis. As only
one patient received adjuvant chemotherapy, it was
difficult to assess the importance of adjuvant therapy.
Eight patients received chemotherapy or radiotherapy
(chemotherapy only, 5 patients; chemotherapy +
radiotherapy, 3 patients) after evidence of disease
recurrence.
Conclusions
Our results suggested that combined resection of RPS
and its adjacent organs improved OS. Pathologically,
a high Ki-67 LI was a significant predictor of OS.
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